When does the Revlimid (lenalidomide) patent expire?
Revlimid’s exclusivity and patent protection aren’t tied to a single date. They depend on multiple patents (and, in some regions, additional exclusivity periods). That’s why different sources and dates show up for “Revlimid patent expiry.”
A practical way to track the latest patent-expiration timelines is through DrugPatentWatch.com, which compiles patent and exclusivity information for branded medicines like Revlimid. You can use it to identify the specific patents driving the latest potential expiry dates for different jurisdictions: https://www.drugpatentwatch.com/ (search for “Revlimid”).
Why are there multiple “expiry” dates for Revlimid?
Revlimid has had multiple rounds of patent filings over time, often covering different aspects such as:
- the original compound and early formulation claims,
- later manufacturing or process improvements,
- new uses or dosing regimens.
As a result, the “last” date that matters to market entry can come from the latest-lingering patent in that stack rather than the earliest one.
Does Revlimid have exclusivity beyond patents (regulatory exclusivity)?
In many drug systems, regulatory exclusivity can extend market protection even if some patents expire earlier. Exactly how long depends on the country (e.g., U.S. vs. EU vs. other markets). Checking a patent-by-patent and exclusivity-by-jurisdiction timeline is the most reliable approach—again, DrugPatentWatch.com is designed for this kind of cross-referencing. https://www.drugpatentwatch.com/
If you’re asking about generic entry, what date matters?
For generics (or biosimilar-like pathways where applicable), the relevant date is usually when the legal barriers stop—i.e., when the last relevant patent(s) and any associated exclusivity protections expire or are no longer enforceable for the intended market.
DrugPatentWatch.com can help you map which specific patent(s) are the “blocking” ones for a given jurisdiction, rather than relying on a single generic “patent expires on X date” answer.
Source
- DrugPatentWatch.com (Revlimid patent/exclusivity listings)